Trade

with

Rigel Pharmaceuticals Inc
(NASDAQ: RIGL)
AdChoices
1.79
+0.06
+3.64%
After Hours :
-
-
-

Open

1.81

Previous Close

1.73

Volume (Avg)

544.37k (546.31k)

Day's Range

1.79-1.81

52Wk Range

1.70-5.00

Market Cap.

151.88M

Dividend Rate ( Yield )

-

Beta

1.29

Shares Outstanding

87.79M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Not Available
    • Revenue

    • 7.15M

    • Net Income

    • -89.03M

    • Market Cap.

    • 151.88M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -1,537.03

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 1.29

    • Forward P/E

    • -2.14

    • Price/Sales

    • 26.32

    • Price/Book Value

    • 0.92

    • Price/Cash flow

    • -2.05

      • EBITDA

      • -86.44M

      • Return on Capital %

      • -39.80

      • Return on Equity %

      • -43.03

      • Return on Assets %

      • -39.80

      • Book Value/Share

      • 1.89

      • Shares Outstanding

      • 87.79M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      -
      Not Available
        • 1 Year Price Target

        • 3.00

        • Credit Rating

        • -

        • Analysts

        • 0

        • EPS Estimate

        • -0.81

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 0.00

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • -

          • -26.33

          • Net Income

            Q/Q (last year)

          • -

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • -

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 100.00

            • 64.72

            • Pre-Tax Margin

            • -1,537.03

            • 13.77

            • Net Profit Margin

            • -1,537.03

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • 100.00

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -4,460.60

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • -4,458.10

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.33

              • Current Ratio

              • 17.64

              • 1.52

              • Quick Ratio

              • 17.49

              • 0.87

              • Interest Coverage

              • -

              • 6.77

              • Leverage Ratio

              • 1.10

              • 1.91

              • Book Value/Share

              • 1.89

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -1.76

                • 63.29

                • P/E Ratio 5-Year High

                • -11.32

                • 237.47

                • P/E Ratio 5-Year Low

                • -1.73

                • 19.71

                • Price/Sales Ratio

                • 27.10

                • 3.53

                • Price/Book Value

                • 0.94

                • 3.31

                • Price/Cash Flow Ratio

                • -2.05

                • 21.23

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -43.03

                    (-38.60)

                  • 7.86

                    (9.58)

                  • Return on Assets %

                    (5-Year Average)

                  • -39.80

                    (-32.40)

                  • 4.14

                    (5.54)

                  • Return on Capital %

                    (5-Year Average)

                  • -43.03

                    (-38.20)

                  • 5.59

                    (7.66)

                  • Income/Employee

                  • -

                  • 27.79k

                  • Inventory Turnover

                  • -

                  • 1.80

                  • Asset Turnover

                  • 0.03

                  • 0.38

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -89.47M
                  Operating Margin
                  -1,251.31
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -2.05
                  Ownership

                  Institutional Ownership

                  85.56%

                  Top 10 Institutions

                  57.18%

                  Mutual Fund Ownership

                  40.66%

                  Float

                  89.41%

                  5% / Insider Ownership

                  0.34%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity® Growth Company Fund

                  •  

                    5,145,017

                  • 0.40

                  • 5.86

                  • Oppenheimer Global Opportunities

                  •  

                    5,000,000

                  • 0.00

                  • 5.70

                  • Fidelity® Select Biotechnology Portfolio

                  •  

                    2,714,951

                  • 0.15

                  • 3.09

                  • UBS (Lux) EF Biotech (USD)

                  •  

                    1,868,100

                  • 0.00

                  • 2.13

                  • Vanguard Total Stock Mkt Idx

                  •  

                    1,474,224

                  • 0.00

                  • 1.68

                  • iShares Russell 2000 (AU)

                  •  

                    1,368,436

                  • -1.01

                  • 1.37

                  • Fidelity® Series Growth Company Fund

                  •  

                    1,242,600

                  • 0.38

                  • 1.42

                  • iShares Nasdaq Biotechnology

                  •  

                    1,173,494

                  • 3.08

                  • 1.18

                  • Vanguard Extended Market Index Fund

                  •  

                    1,092,038

                  • 0.39

                  • 1.24

                  • Fidelity® Select Health Care Portfolio

                  •  

                    1,081,800

                  • 0.30

                  • 1.23

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Fidelity Management and Research Company

                  •  

                    13,129,697

                  • 0.00%

                  • 15.00

                  • Wellington Management Company, LLP

                  •  

                    6,156,658

                  • +37.59%

                  • 7.03

                  • Broadfin Capital, LLC

                  •  

                    5,598,019

                  • +2.62%

                  • 6.40

                  • Palo Alto Investors, LLC

                  •  

                    5,180,101

                  • -49.90%

                  • 5.92

                  • OppenheimerFunds, Inc.

                  •  

                    5,000,000

                  • 0.00%

                  • 5.71

                  • Vanguard Group, Inc.

                  •  

                    4,117,277

                  • +0.10%

                  • 4.70

                  • BlackRock Fund Advisors

                  •  

                    3,329,362

                  • +3.96%

                  • 3.80

                  • NEA Management Company, LLC

                  •  

                    3,243,150

                  • 0.00%

                  • 3.71

                  • Deerfield Management Co

                  •  

                    2,397,855

                  • +133.38%

                  • 2.74

                  • UBS Global Asset Management Zurich

                  •  

                    1,900,196

                  • 0.00%

                  • 2.17

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Specific & Generic

                  Type

                  Distressed

                  Style

                  Small Value

                  Rigel Pharmaceuticals Inc was incorporated in the state of Delaware on June 14, 1996. The Company is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory ...moreand autoimmune diseases, as well as muscle disorders. The Companys pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. The Company currently has five product candidates in development: fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor entering in Phase 3 clinical trials for immune thrombocytopenic purpura (ITP) and a Phase 2 clinical trial for immunoglobulin A nephropathy (IgAN) in the first half of 2014; R348, a topical JAK/SYK inhibitor currently in Phase 2 clinical trials for dry eye; ...moreR118, an adenosine monophosphate (AMP)-activated protein kinase (AMPK) activator entering Phase 1 in the first half of 2014; and two oncology product candidates in Phase 1 development with partners BerGenBio AS and Daiichi Sankyo, respectively. The Company is conducting proprietary research in the broad disease areas of inflammation/immunology and muscle wasting/muscle endurance. The Companys major competitors include fully integrated pharmaceutical companies that have extensive drug discovery efforts and are developing novel small molecule pharmaceuticals. The Company is subject to extensive regulation by numerous governmental authorities in the United States and other countries, including the FDA under the Federal Food, Drug and Cosmetic Act.lessless

                  Key People

                  James M. Gower

                  CEO/Chairman of the Board/Director

                  Dr. Donald G. Payan,M.D.

                  Co-Founder/Director/Executive VP/President, Divisional

                  Ryan D. Maynard

                  CFO/Chief Accounting Officer/Executive VP

                  Dolly A. Vance

                  Executive VP, Divisional/General Counsel/Secretary

                  Dr. Elliott B. Grossbard,M.D.

                  Executive VP/Chief Medical Officer

                  • Rigel Pharmaceuticals Inc

                  • 1180 Veterans Boulevard

                  • South San Francisco, CA 94080

                  • USA.Map

                  • Phone: +1 650 624-1100

                  • Fax: +1 650 624-1101

                  • rigel.com

                  Incorporated

                  1996

                  Employees

                  129

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: